

ASCEPT Virtual Annual Scientific Meeting

29 NOV – 2 DEC 2021

20/20 Hindsight – creating a sustainable future for pharmacology and toxicology



#ASCEPT2021
www.asceptasm.com

Scientific program (as at 5 November 2021)

Thank you to our meeting sponsors and supporters.

Principal sponsor



Major sponsors



Key sponsors



Networking sponsor



Poster sponsor



Meeting supporters



Society friends



Monday 29 November 2021 | 11.00am – 4.00 pm Australian Eastern Daylight Time (AEDT)

Pre-meeting Special Interest Group Workshops

11.00am – 1.00pm Morning workshops

Education Forum

Facilitator: Dr Angela Finch, UNSW Sydney

11.00am – 12.00pm Innovations in Education from across ASCEPT-Panel Discussion

This session will highlight innovative educational approaches that our members have developed to enhance the teaching of topics that reflect the diversity of pharmacology represented by our special interest groups.

Videos from each speaker will be made available for viewing before the session. Join us for a panel discussion to learn more about fantastic work happening in this space.

12.00pm – 12.30pm Follow-up from challenges and adventures in hybrid teaching mid-year workshop

This session will invite participants to reflect on their experiences with hybrid (online and face to face) teaching and share success and/or failures of different approaches/projects they have tried.

12.30pm – 1.00pm Education Forum AGM

Drug Discovery workshop

Application of artificial intelligence and computational tools in drug discovery

Facilitators: Dr Katie Leach, Dr Michelle Halls and Assoc Prof Denise Wootten, Monash University

Sponsored by Drug Discovery Biology



Overview: This workshop is designed to introduce researchers to the core concepts in artificial intelligence (AI) and high-performance computing (HPC), the fundamentals to get started with using AI, and to provide examples of how these approaches can be utilised in pharmacological research and drug discovery.

11.00am – 12:10pm Deep Learning Workshop – Theory and Concepts

Chair: Dr Michelle Halls, Monash University
Facilitator: Monash DeepNeuron; a student-led non-profit engineering team that promote accessibility of AI and HPC.



12.10pm – 12.40pm Exploiting computational approaches to facilitate G protein-coupled receptor pharmacology and drug discovery.

Chair: Assoc Prof Denise Wootten, Monash University
Alex Hauser, University of Copenhagen

12.40pm – 13.00pm Panel discussion/ Q&A

Moderator: Dr Katie Leach, Monash University
Panel members: Monash DeepNeuron members, Alex Hauser

Pharmacogenomics workshop

Facilitator: Prof Andrew Somogyi, The University of Adelaide

No one and no disease gets left behind – progressing the clinical implementation of pharmacogenomics

11.05am – 11.35am Translating Pharmacogenomics in Mental Health Care

Assoc Prof Kathy Wu, St Vincent's Hospital

11.35am – 12.10pm U-PGx: Design and Netherlands Implementation

Assoc Prof Jesse Swen, Leiden University Medical Center, The Netherlands

12.10pm – 12.25pm Pharmacogenomic testing: Perception of clinical utility, and enablers and barriers to adoption in Australian hospitals

Dr Sophie Stocker, The University of Sydney

12.25pm – 12.40pm Closing the Loop: Pharmacogenetics in Australian Pharmacies

Mr Nicholas Haddrick, Honours student, The University of Canberra

12.40pm – 1.00pm AGM

2.00pm – 4.00pm Afternoon workshops

Careers workshop

Facilitators: Dr Betty Exintaris and Assoc Prof Barbara Kemp-Harper, Monash University

The purpose of this workshop will be to hear from professionals in education, industry, government and research who have transitioned from or stayed in research. The format will include individual presentations, a panel discussion and networking in breakout rooms. The speakers are:

- Ms Katie Martin, Policy Officer at the Australian Government Department of Health, Canberra
- Prof Mark Hutchinson, Director of the ARC Centre of Excellence for Nanoscale BioPhotonics, University of Adelaide
- Assoc Prof Tamara Paravicini, STEM College, RMIT University
- Dr Preet Chadha, Senior Medical Manager (Oncology), AstraZeneca

Clinical Pharmacology workshop:

To TDM or not to TDM, that is the question!

Chair: Assoc Prof Darren Roberts, St Vincent's Hospital Sydney; University of New South Wales

Presenters: Scientists and Clinicians from the Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital Sydney

Overview: This workshop will explore decision-making regarding the use of therapeutic drug monitoring (TDM; or Target Concentration Intervention, TCI) in clinical practice, with a focus on antibiotics.

Part 1: Presentation providing an overview of the topic. Participants will review criteria/characteristics/conditions described in the literature, propose others as needed, and reflect on whether any should be rated of greater or lesser importance.

Part 2: In groups, participants will apply these criteria to the scenario of linezolid, an antibiotic for which TDM is possible, but not currently routine

Part 3: Participants will reflect on findings by each group and consider the question "Does the current evidence support linezolid TDM in routine clinical care?". Participants will discuss any research questions prompted by these discussions, their priority, and how these can be addressed by the Australasian clinical pharmacology community.

Tuesday 30 November 2021 | 12.00 – 5.40 pm Australian Eastern Daylight Time (AEDT)

12.00 – 12.46 Meeting opening and opening keynote presentation

Assoc Prof Danijela Gnjidic, ASCEPT President
Dr Nicola Smith, ASCEPT Acting SAC Chair

Supported by



Chair: Prof Kevin Pflieger, University of Western Australia
REMAP-CAP: Testing everything at once for severe COVID
Prof Steve Webb, Royal Perth Hospital

12.48 – 1.08 Concurrent session

Meet the speaker discussion with Prof Steve Webb
(20 pre-registered participants)

Time to view ePosters and visit the sponsors' portal

1.08 – 1.14 Break

1.15 – 2.15 Concurrent 1 symposium sessions

Symposium 1: Targeting GPCRs to treat cardiometabolic disease

Supported by
 **MONASH University**
Institute of Pharmaceutical Sciences

Co-chairs: Assoc Prof Denise Wootten, Monash University and Prof Chrishan S Samuel, Monash University

The cardiometabolic phenotype of orphan GPR37L1: Not all mice are created equal
Dr Nicola Smith, UNSW Sydney

Understanding the physiological consequences of biased agonism at the GLP-1R
Dr Elva Zhao, Monash University

Regulation of GPCR signalling at adrenergic receptor
Prof Walter J Koch, Temple University, Pennsylvania, USA

Resolving inflammation as an emerging approach to treat vascular complication
Dr Chengxue Helena Qin, Monash University

Symposium 2: How do we authentically skill our graduates?

Co-chairs: Dr Angela Finch and Ms Meg Mouat, UNSW Sydney

"Threshold vs mastery": A new way to teach and assess.
Dr Shannan Maisey, UNSW Sydney

Skills priorities for a future ready workforce
Prof Kevin Pflieger, University of Western Australia

Decision-making by reflection: An interprofessional experience
Ms Aynsley Peterson, University of Otago, New Zealand

Panel discussion

Symposium 3: Pharmacological development of new medicines for heart failure

Supported by
 **ACvA**
Australian Cardiovascular Alliance

Co-chairs: Dr Louise See Hoe, The University of Queensland and The Prince Charles Hospital and Dr Miles De Blasio, Baker Heart and Diabetes Institute

Targeting GPCRs for the development of new heart failure therapeutics
Dr Lauren May, Monash University

Bromodomain-containing protein inhibition as a therapeutic strategy in heart failure
Dr Simon Foster, QIMR Berghofer Medical Research Institute

Pharmacological development of new medicines for heart failure
Prof Peter Molenaar, The University of Queensland

Novel approaches to heart preservation during transplantation - Hypothermic Ex Vivo Perfusion
Dr Louise See Hoe, The University of Queensland and The Prince Charles Hospital

2.15 – 2.29 Break

Supported by



2.30 – 3.55 Concurrent 2 oral sessions

Oral presentations 1: Education Forum

Supported by



Oral presentations 2: Drug Discovery

Co-chairs: Dr Nicholas Hunt and Ms Silke Chalmers

Characterisation of chemokine GPCRs signalling in monocytes using state-of-the-art phosphoproteomics approach
Miss Rina Pokhrel, Monash University

Oral presentations 3: Cardiovascular

Co-chairs: Dr Michael De Silva and Dr Melissa Reichelt

Combined antiplatelet/ anticoagulant drug for cardiac ischemia/reperfusion injury
Dr Laura Bienvenu, Baker Heart and Diabetes Institute

Oral presentations 4: Clinical Pharmacology

Co-chairs: Dr Catherine Lucas and Dr Frida Djukiadmodjo

Antidepressant deprescribing recommendations in clinical practice guidelines for depression: systematic review
Miss Patricia Yee, The University of Sydney

Program continued on next page

Tuesday 30 November 2021 | continued 12.00 – 5.40 pm Australian Eastern Daylight Time (AEDT)

Oral presentations 1: Education Forum	Oral presentations 2: Drug Discovery	Oral presentations 3: Cardiovascular	Oral presentations 4: Clinical Pharmacology
Attendance but not delivery mode correlates with academic performance in a newly developed pharmacology subject Assoc Prof Elvan Djouma, La Trobe University	The cardiometabolic expression profile of the sweet taste receptor Miss Mariah Stavrou, UNSW Sydney	Inactivation of the local cardiac renin angiotensin system improves cardiac performance after myocardial infarction Ms Zunhan Lu, The University of Queensland	A stewardship program to facilitate anticholinergic and sedative medication deprescribing using the Drug Burden Index integrated in Electronic Medical Records Dr Nashwa Masnoon, The University of Sydney and Royal North Shore Hospital
Using a design thinking approach to develop a large-scale, inter-professional medication safety micro-curriculum Assoc Prof Kellie Charles, The University of Sydney	Novel targeted nanotheranostic delivery systems for precision therapy of triple negative breast cancer Dr Pegah Varamini, The University of Sydney	Activation of the Angiotensin II type 2 receptor prevents progression of cardiac fibrosis associated with hypertension and concomitant diabetes Miss Mandy Li, Monash University	Deprescribing paracetamol in pain conditions: A scoping review Mr Thomas Patterson, The University of Sydney
Upskilling Teaching Associates: A bespoke Virtual Teaching Associate Training program Dr Betty Exintaris, Monash University	Afatinib is a novel and effective drug candidate for the treatment of human uveal melanoma Assoc Prof Fanfan Zhou, The University of Sydney	Targeting formyl peptide receptors as a novel approach to treat hypertension-induced end-organ damage Mr Jaideep Singh, Monash University	OPTIMIZE: A pragmatic cluster randomized deprescribing trial in primary care Dr Emily Reeve, University of South Australia
Nimble pharma®: Pandemic pivoting to a synchronous proxy practical class examining new treatments for COVID-19 Dr Graham Mackay, The University of Melbourne	The adenosine A2B receptor accelerates invasion in aggressive triple negative breast cancer tumour cells Miss Sandra Surssock, Monash University	Human amnion epithelial cells reduce blood pressure and prevent aortic inflammation and collagen expression during experimental hypertension Dr Quynh Nhu Dinh, La Trobe University	Effect of self-monitoring urate on allopurinol adherence Mr Jian Chan, UNSW Sydney

3.55 – 3.59 Break

4.00 – 4.30 ASCEPT Early Achievement Award for Women

Chair: Assoc Prof Danijela Gnjidic, The University of Sydney

The development and application of BRET-based assays to characterise molecular pharmacology

Dr Elizabeth KM Johnstone, Harry Perkins Institute of Medical Research and University of Western Australia

4.30 – 4.55 British Pharmacological Society keynote presentation

Chair: Assoc Prof Danijela Gnjidic, The University of Sydney

Tackling dementia: From structure to clinic targeting muscarinic receptors

Prof Andrew Tobin, The University of Glasgow, UK

5.00 – 5.45 Concurrent 3 session

5.00 – 5.20 Meet the speaker discussion with BPS speaker, Prof Andrew Tobin
(20 pre-registered participants)

Discussion group: The challenges of symposia and EDI
Facilitator: Assoc Prof Tina Hinton, The University of Sydney
 (20 pre-registered participants and repeated on Thurs 2 Dec)

Time to view ePosters and visit the sponsors' portal

Wednesday 1 December 2021 | 12.00 – 5.45 pm Australian Eastern Daylight Time (AEDT)

9.00 – 11.29 Time to view ePosters and visit the sponsors' portal			
10.00 – 11.00 The 55th Annual General Meeting of ASCEPT (via Zoom)			
11.30 Commencement of day two presentations			
11.30 – 12.40 Poster presentations by award finalists Chairs: Dr Nicola Smith, UNSW Sydney and Assoc Prof Kellie Charles, The University of Sydney			
12.40 – 12.50 Break			
12.50 – 1.20 ASCEPT Gillian Shenfield Early Educator Award Chair: Dr Angela Finch, UNSW Sydney Skills coaching: An innovative initiative to support professional skill development in pharmacology students Dr Nilushi Karunaratne, Monash University			
1.20 – 1.50 Japanese Pharmacological Society (JPS) keynote presentation Chair: Assoc Prof Danijela Gnjidic, The University of Sydney Unbiased and hypothesis-free approaches to studying the brain and its disorders using whole-brain imaging technique Prof Hitoshi Hashimoto, Osaka University, Japan			
1.50 – 2.10 Concurrent session			
Time to view ePosters and visit the sponsors' portal		Meet the speaker discussion with JPS speaker, Prof Hitoshi Hashimoto	
2.10 – 2.30 Break			
2.30 – 3.55 Concurrent 4 oral sessions			
Oral presentations 5: Urogenital and Gastrointestinal and Toxicology	Oral presentations 6: Drug Discovery Supported by  	Oral presentations 7: Cardiovascular and Respiratory and Inflammation	Oral presentations 8: Clinical Pharmacology and Drug Disposition and Response
Co-chairs: Dr Iris Lim and Dr Jane Carland	Co-chairs: Dr Simon Foster and Dr Elizabeth Johnstone	Co-chairs: Dr Tracey Gaspari and Dr Simone De Luca	Co-chairs: Dr Frank Reimann and Assoc Prof Cornelia Landersdorfer
Gamma-hydroxybutyrate overdose in inner-Sydney Emergency Departments: A retrospective review Mr Oliver Harris, UNSW Sydney	Structural insights into allosteric modulation of the human glucagon-like peptide-1 receptor Dr Xin Zhang, Monash University	Human amniotic epithelial cells reduce brain injury after tissue plasminogen activator therapy in ischemic stroke Miss Liz Barreto Arce, La Trobe University	Targeting hypermutable Pseudomonas aeruginosa clinical isolates with inhaled aztreonam and tobramycin dosing regimens in a dynamic in vitro biofilm model Miss Siobhonne Breen, Monash University
Polypharmacy with high Drug Burden Index (DBI): Association with microbiome and global function in aged mice Miss Gizem Gemikonakli, The University of Sydney	Ligand-directed G protein coupling and downstream signalling of the GLP-1R Mr John Azietaku, Monash University	Inhibition of oxidative stress prevents the onset of glucose intolerance associated with cigarette smoking Dr Stanley Chan, RMIT University	Polypharmacy with high Drug Burden Index affects physical performance differently in mice of varying age and sex, over 23 hours Ms Trang Tran, The University of Sydney
Chloroacetaldehyde, the toxic urinary metabolite of cyclophosphamide, alters urinary bladder function Ms Eleanor West, Bond University	The importance of a methylene group in the species variability of VU0467154 at the M4 muscarinic receptor Dr Emma van der Westhuizen, Monash University	Metabolic profiling of mice with deletion of orphan GPCR, GPR37L1 Ms Margaret Mouat, UNSW Sydney	Tobacco cessation medications in tobacco smokers receiving treatment for opioid use disorder Ms Catherine Lobbe, University of New England and The University of Newcastle
In vitro demonstration of herbal exacerbation of paracetamol-induced hepatotoxicity Ms Susan Britza, The University of Adelaide	Orthosteric or Allosteric: Implications for determining mechanisms of probe dependence Mr Wessel Burger, Monash University	Influenza A virus induces peri-vascular adipose tissue inflammation and vascular dysfunction in pregnant mice Mr Osezua Oseghale, RMIT University	Comparing effects of polypharmacy on inflammatory profiles in older adults and mice: Implications for translational ageing research Dr Harry Wu, The University of Sydney
Expression and localisation of mas-related G protein-coupled receptors F and D: A novel study in the human colon Mr Patrick Hawker, UNSW Sydney	Less is more when it comes to allosteric modulation of the M1 muscarinic receptor Mrs Huong Nguyen, Monash University	Single cell transcriptomic profiling of the hypertensive mouse aorta Miss Tayla Hughes, La Trobe University	Efficacy of second-line vasopressors in the critically ill Miss Jasmine Li, The University of Sydney

Wednesday 1 December 2021 | continued 12.00 – 5.45 pm Australian Eastern Daylight Time (AEDT)

3.55 – 4.10 Break

4.10 – 5.10 Concurrent 5 symposium session

Symposium 4: Finding the keys in the dark: determining the pharmacology of orphan GPCRs	Symposium 5: Preparing health professional graduates for safe and rational prescribing - current and future opportunities	Symposium 6: Advancing adherence management in the clinical setting
	Supported by  BRITISH PHARMACOLOGICAL SOCIETY	
Co-chairs: Dr Nicola Smith and Ms Kinjal Patel, UNSW Sydney	Co-chairs: Prof Sarah Hilmer, Royal North Shore Hospital and The University of Sydney and Assoc Prof Matthew Doogue, Christchurch Hospital and University of Otago, New Zealand	Chair: Dr Sophie Stocker, The University of Sydney
The orphan GPCR GPR101 contributes to growth hormone secretion via constitutive activation of Gs and Gq/11 Dr Julien Hanson, University of Liege, Belgium	The National Prescribing Curriculum – supporting confident and rational prescribing by health professional graduates Clare Weston, NPS MedicineWise	Impact of adherence on HIV, malaria, and TB treatment and prevention Prof Rada Savic, University of California San Francisco, USA
Orphan GPR146 regulates blood cholesterol levels in humans and mice Dr Yan Wang, Wuhan University, China	Recent developments with the PSA - application to other disciplines and other countries Prof Simon Maxwell, University of Edinburgh, Scotland	A decision support tool for the management of adherence in patients with gout Dr Daniel Wright, University of Otago, New Zealand
Do RAMP and MRAP accessory proteins modulate orphan putative cannabinoid receptors GPR18 and GPR55? Dr Natasha Grimsey, University of Auckland, New Zealand	The Prescribing Skills Assessment (PSA) - a journey across Australia and New Zealand, its progress, evaluation and future plans Assoc Prof Claire Harrison, Monash University	Adherence monitoring in medication assisted treatment of opioid dependence Assoc Prof Bridin Murnion, University of Newcastle
GPR52 and its role in cognition Dr Greg Stewart, Monash University	A programmatic interprofessional approach to prescribing education: Medication safety as a team sport Assoc Prof Kellie Charles and Dr Carl Schneider, The University of Sydney	Estimating forgiveness using trials of placebo-substituted active drugs Prof Dyfrig Hughes, Bangor University, Wales

5.15 – 5.45 British Toxicology Society (BTS) keynote presentation

Chair: Assoc Prof Danijela Gnjidic, The University of Sydney
New perspectives on drug safety and the mitochondria: from toxicological target to personal susceptibility factor
Dr Amy Chadwick, Department of Pharmacology and Therapeutics, The University of Liverpool, UK

5.45 – 6.30 Networking function

Supported by



Thursday 2 December 2021 | 11.30am – 4.45 pm Australian Eastern Daylight Time (AEDT)

9.00 – 11.59 Time to view posters and visit the sponsors' portal

11.30 – 12.15 Concurrent session 6

Discussion group: The challenges of symposia and EDI
Facilitator: Assoc Prof Tina Hinton, The University of Sydney
 (20 pre-registered participants. Repeat of session held on Tues 30 Nov).

Time to view ePosters and visit the sponsors' portal

12.15 – 12.30 Break

12.30 – 2.00 Certara New Investigator Award

Chair: Assoc Prof Danijela Gnjidic, The University of Sydney

Supported by



Novel targets for the treatment of chronic pelvic pain
 Dr Luke Grundy, Flinders University

Oral Nanotherapeutic formulations of Insulin
 Dr Nicholas Hunt, The University of Sydney

RAMPing up dynamics at G protein coupled receptors
 Dr Tracy Josephs, Monash University

Dr Madele van Dyk, Flinders University

2.00 – 2.15 Break

2.15 – 3.55 Concurrent 7 oral sessions

ASCEPT Garth McQueen student oral prize	Oral presentations 9: Pharmacoepidemiology and Clinical Pharmacology Trainee	Oral presentations 10: Neuropharmacology and Respiratory and Inflammation	Oral presentations 11: Clinical Pharmacology and Pharmacogenomics
Co-chairs: Dr Nicola Smith and Assoc Prof Kellie Charles	Co-chairs: Assoc Prof Gillian Caughey and Dr Nicholas Farinola	Co-chairs: Dr Luke Grundy and Dr Carl White	Co-chairs: Dr Suong Ngo and Mr Sam Mostafa
GPCR-CoINPocket identifies peptide GPCR ligands with novel off-target activity on the β_2 adrenoceptor Mr Sean So, UNSW Sydney	COVID-19 restrictions and the incidence and prevalence of prescription opioids in Australia Ms Monica Jung, Monash University	Cigarette smoking is associated with circadian rhythm disruption in mice Dr Simone De Luca, RMIT University	Exploration of time-dependent clearance associated with busulfan treatment in paediatrics Ms Rachael Lawson, The University of Queensland
Formyl peptide receptor agonists as novel vasodilators and anti-inflammatories for pulmonary hypertension Mr William Studley, Monash University	Development of a tool to evaluate medication management guidance provided to carers of people living with dementia at hospital discharge Dr Mouna Sawan, The University of Sydney	Effect of the ubiquitin E3 ligase NEDD4-1 on P-gp expression, activity and export of Alzheimer's Aβ peptides Miss Amanda Chai, The University of Sydney	Population pharmacokinetics and exposure-response analyses for allopurinol in patients with gout Mr Hailemichael Hishe, University of Otago, New Zealand
Opioid deprescribing guidelines: Moving from evidence to practice Ms Aili Langford, The University of Sydney	Adverse drug reaction-related hospitalisations among people with dementia Miss Anum Zaidi, University of Tasmania	Novel antibodies targeting dopamine D2 receptor phospho-sites allow evaluation of reported biased agonists Dr Alastair Keen, Monash University	A population pharmacokinetic model to inform tacrolimus therapy in heart transplant recipients Ms Ranita Kirubakaran, UNSW Sydney
Pharmacological inhibition or genetic deficiency of insulin regulated aminopeptidase (IRAP) protects against UUO-induced renal injury in mice Miss Sharenya Chelvaretnam, Monash University	Pilot study assessing intestinal toxicity in acute self-poisoning using a novel biomarker Intestinal Fatty Acid Binding Protein Dr Varan Perananthan, Royal Prince Alfred Hospital	Investigating the correlation between genotype and clinical phenotypes of GABAA receptor variants Mr Tsz Yuen Jonas Lok, The University of Sydney	A Natural Language Processing Machine-Learning Model for the Detection of Adverse Drug Reactions Miss Julia Chan, Austin Health, The University of Melbourne
Small molecule Drp1 inhibitors for cardioprotection Ms Ayesha Augusta Rosdah, The University of Melbourne	Changes in tapentadol prescribing and harm relative to oxycodone in a tertiary healthcare setting Dr Frida Djukiadmodjo, Austin Health	Habitual cigarette smoke exposure evokes anxiety-like behaviour in mice which is associated with neuroinflammation and oxidative stress of the amygdala Mrs Rana Alateeq, RMIT University	Psychometric evaluation of the Adherence to Refills and Medications Scale (ARMS) in Australians living with gout Mr Marcel Schulz, UNSW Sydney

Program continued on next page

Thursday 2 December 2021 | continued 11.30 – 4.45 pm Australian Eastern Daylight Time (AEDT)

<p>Insulin regulated aminopeptidase (IRAP) inhibition attenuates diabetes-induced cardio-renal pathology and vascular dysfunction in mice Mr Cameron Hollands, Monash University</p>	<p>Efficacy and safety of Vedolizumab in older adults with Inflammatory Bowel Disease: A systematic review and meta-analysis Dr Justin Baker, Flinders Medical Centre</p>	<p>Apocynin improves working memory impairments in a mouse model of Chronic Obstructive Pulmonary Disease Miss Alina Akhtar, RMIT University</p>	<p>Pharmacogenomic testing: Perception of clinical utility, and enablers and barriers to adoption in Australian hospitals. Dr Sophie Stocker, The University of Sydney</p>
<p>3.55 – 4.05 Break</p>			
<p>4.05 – 4.35 RAND Medal Lecture Chair: Assoc Prof Danijela Grnjidic, The University of Sydney Prof Christopher Sobey, La Trobe University</p>			
<p>4.35 – 4.45 Meeting close and awards Prof Kevin Pflieger, ASCEPT President Elect</p>			